Biotech Co.*
(Country; Symbol)		 Pharma Co. (Country) Type/Product Area Terms/Details (Date)
Actelion Ltd. (Switzerland; SWX:ATLG) GlaxoSmithKline plc (UK) Strategic collaboration in the area of orexin antagonists Deal could be worth up to CHF3.3 billion ($3.2 billion) in up-front, development and sales-related milestones; it focuses on almorexant, which is in Phase III for primary insomnia (7/14)
 
Altea Therapeutics Inc.* Hospira Inc. Agreement to develop and commercialize an undisclosed product using Altea's PassPort transdermal delivery system The deal is worth up to $109M; Altea agreed to fund certain Phase I studies, after which Hospira will take over further development, manufacturing and commercialization activities, and Altea stands to receive an undisclosed up-front payment, which includes an equity investment (7/2)
 
Addrenex Pharmaceuticals Inc.* Sciele Pharma Inc. Licensing agreement for rights to a compound for hypertension and other indications The deal is worth up to $27M in development and regulatory milestone payments and future royalty payments on product sales (7/2)
 
Amgen Inc. (AMGN)  Ortho-Biotech Products LP (subsidiary of Johnson & Johnson)  Agreement to settle an antitrust lawsuit regarding Amgen's infection drugs Neupogen and Neulasta and its anemia drug Aranesp Ortho said the bundling of the drugs drove down sales of its anemia drug Procrit; Amgen paid Ortho $200M to settle the suit (7/14)
 
Clinical Data Inc. (CLDA) H. Lundbeck AS (Denmark) Scientific research and development agreement to support the clinical studies of Clinical Data's Cogenics division with genotyping solutions on a global basis Cogenics will use its clinical genotyping platforms and expertise to support Lundbeck's clinical studies worldwide (7/15)
 
Immunomedics Inc. (IMMU)  Nycomed GmbH (Switzerland) Agreement giving Nycomed worldwide rights in all indications except cancer to the subcutaneous formulation of Immunomedics' humanized anti-CD20 anti-body, veltuzumab Immunomedics will get $40M up front and up to $580M in milestone payments, as well as escalating double-digit royalties (7/15)
 
Maxygen Inc. (MAXY) Bayer HealthCare Licensing agreement for early stage hemophilia candidate, MAXY-VII The deal involves $90M in cash up front and potentially $30M more in milestones down the road (7/2)
 
Proximagen Neuroscience plc (UK; LSE:PRX) Upsher-Smith Laboratories Inc. Development agreement for PRX1, a preclinical-stage compound that is an improved formulation of L-Dopa, for the symptomatic treatment of Parkinson's disease The deal includes an up-front payment and milestone payments totaling up to $232M, which will include a $6M equity investment in Proximagen at about $3.99 per share; Proximagen also is entitled to  double-digit royalties (7/14)
 
Seattle Genetics Inc. (SGEN)  Daiichi Sankyo Co. Ltd. (Japan) Development agreement for the manufacturing and commercialization of ADCs that target a single antigen found on multiple types of solid tumors The deal includes $4M up front, as well as milestone payments and royalties on worldwide sales stemming from any ADC-based products that Sankyo develops (7/8)
 
Sigma-Aldrich Corp. (SIAL) and Sangamo BioSciences Inc. (SGMO) F. Hoffmann-La Roche (Switzerland) Research and license agreement for nonexclusive worldwide rights for the use of its zinc finger nuclease technology to develop cell-lines and transgenic animals that have targeted modifications in a specified gene in a specified species Roche also has an option to obtain an exclusive, worldwide license for the commercial use of such ZFN-generated transgenic animals in the production of therapeutic and diagnostic products (7/9)
Notes:

# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk. ** Denotes the date the item ran in BioWorld International.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

LSE = London Stock Exchange; NYSE = New York Stock Exchange; SWX = Swiss Stock Exchange.